AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06121700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: The investigator's choice of chemotherapy regimens included SOX, XELOX or FOLFOX. Their usages are as follows:~SOX: S-1 twice a day, days 1-14, the dose of S-1 is accorded to body-surface area (BSA): patients with a BSA of less than 1.25 m2 receive 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 receive 100 mg daily; and those with a BSA of 1.5 m2 or more receive 120 mg daily; and oxaliplatin 130 mg/m2, day 1, every 3 weeks; XELOX: Capecitabine 1000 mg/m2 twice a day, days 1-14 and oxaliplatin 130 mg/m2, day 1, every 3 weeks; FOLFOX: Leucovorin 400 mg/m2, day 1, fluorouracil 400 mg/m2, day 1 and 1200 mg/m2, days 1-2, and oxaliplatin 85 mg/m2, day 1, every 2 weeks.
Study NCT06121700 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: R0 total/subtotal gastrectomy with D2 lymphadenectomy
Description: For patients with a good response to preoperative treatment, surgical resection of primary and metastatic lesions is recommended. For primary lesions, gastrectomy with standard D2 lymphadenectomy is commonly used. The type of gastrectomy performed depends on the location and extent of the primary lesion. For GEJ or upper-third tumors, a 3 cm esophageal margin is recommended, and a total gastrectomy or esophagogastrectomy is performed. For middle-third tumors, the gastric margin is recommended to be more than 5 cm, and total gastrectomy is performed. For lower-third tumors, a 2 cm duodenal margin is recommended, and subtotal or total gastrectomy is performed. Billroth I or Roux-en-Y gastrojejunostomy is performed for distal gastrectomy patients. Roux-en-Y esophagojejunostomy is performed for patients receiving total gastrectomy.
Study NCT06121700 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metastasectomy
Description: For patients with a good response to preoperative treatment, surgical resection of primary and metastatic lesions is recommended. For metastatic lesions, the surgical procedure and resection range are determined by the surgeon.
Study NCT06121700 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local ablative therapies
Description: Local ablative therapies such as radiofrequency ablation (RFA) and microwave ablation (MVA) achieve high rates of complete tumor eradication of small metastases, and can be seen as alternatives if a widely invasive surgical approach is required or patient is inoperable.
Study NCT05012319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: to be given as a treatment
Description: Nitric Oxide Nasal Spray Enovid
Study NCT05012319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: to be given as a treatment
Description: Nitric Oxide Nasal Spray Enovid
Study NCT06373445 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation active stimulation
Description: This study was conducted on 20 eligible fibromyalgia patients with sleep disorders. They were randomized to have 20 sessions of active rTMS (1 Hz, 120% of resting motor threshold with total 1200 pules /session) over the right dorsolateral prefrontal area (DLPFC) for 5 sessions/week for 4 weeks.
Study NCT06373445 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation sham stimulation
Description: This study was conducted on 20 eligible fibromyalgia patients with sleep disorders. They were randomized to have 20 sessions of sham rTMS (1 Hz, 120% of resting motor threshold with total 1200 pules /session) over the right dorsolateral prefrontal area (DLPFC) for 5 sessions/week for 4 weeks.
Study NCT05438147 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CT-100 DiNaMo
Description: Active Treatment (Study App)
Study NCT05676736 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention to be done for the group
Study NCT05487768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG measurement
Description: EEG measurement to evaluate functional connectivity in the brain during 3 motor tasks:~* Knee extension while sitting (10x left - right)~* Bipodal squatting (10x)~* Unipodal stance (5x30 seconds left-right)
Study NCT05438147 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Care-as-Usual
Description: Care-As-Usual control
Study NCT05427058 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Superior Hypogastric Plexus Block
Description: this procedure uses a transdiscal approach at the level of the L5-S1 vertebrae by injecting 5 ml of 1% lidocaine + 10 ml of 96% alcohol and confirmed by C-arm.
Study NCT05427058 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ganglion Impar Block
Description: this procedure uses a trans-sacrococcygeal approach by injecting 4 ml of 1% lidocaine + 6 ml of 96% alcohol and confirmed by C-arm.
Study NCT05487768 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EEG measurement
Description: EEG measurement to evaluate functional connectivity in the brain during 3 motor tasks:~* Knee extension while sitting (10x left - right)~* Bipodal squatting (10x)~* Unipodal stance (5x30 seconds left-right)
Study NCT04813562 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: a middle-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56
Description: 18-59 years,Three doses of middle-dose (20µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
Study NCT06074432 — intervention group
Intervention type: OTHER
Intervention: Emergency Colorectal Resection
Description: Patients underwent resection due to colorectal carcinoma in emergency surgery
Study NCT05802901 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal manipulation
Description: Spinal manipulation of the lumbar spine only to be performed in the spinal manipulation arm/group.
Study NCT05802901 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: Dry needling of the lumbar erector spinae, multifidus, and gluteus medius on the symptomatic side performed in the dry needling arm/group.
Study NCT04813562 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: a high-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56
Description: 18-59 years,Three doses of high-dose (40µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
Study NCT04813562 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: a middle-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56
Description: 60-85 years,Three doses of middle-dose (20µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
Study NCT04813562 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: a high-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56
Description: 60-85 years,Three doses of high-dose (40µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
Study NCT04813562 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: a middle-dose placebo (18-59 years) at the schedule of day 0, 28, 56
Description: 18-59 years,Three doses of middle-dose (0.5ml) placebo at the schedule of day 0, 28, 56.
Study NCT04813562 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: a high-dose placebo (18-59 years) at the schedule of day 0, 28, 56
Description: 18-59 years,Three doses of high-dose (0.5ml) placebo at the schedule of day 0, 28, 56.
Study NCT04813562 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: a middle-dose placebo (60-85 years) at the schedule of day 0, 28, 56
Description: 60-85 years,Three doses of middle-dose (0.5ml) placebo at the schedule of day 0, 28, 56.
Study NCT04813562 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: a high-dose placebo (60-85 years) at the schedule of day 0, 28, 56
Description: 60-85 years,Three doses of high-dose (0.5ml) placebo at the schedule of day 0, 28, 56.
Study NCT05802901 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal manipulation and dry needling
Description: The spinal manipulation and dry needling arm/group receive both spinal manipulation and dry needling as outlined in the other groups.
Study NCT03676647 — intervention group
Intervention type: OTHER
Intervention: Diagnostic DNA Methylation Signature
Description: Undergo collection of tissue samples
Study NCT05291052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tisleizumab 200 mg intravenously (IV) every 3 weeks (Q3W) ,D1
Study NCT05291052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 8 mg (for patient weight \< 60 kg) or 12 mg (for patient weight ≥ 60 kg), orally, QD, D1-21, Q3W
Study NCT05291052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 130 mg/m2, IV， D1，Q3W~Subjects can receive up to 8 cycles of the XELOX regimen (Oxaliplatin and Capecitabine). For subjects who are intolerant to XELOX regimen or have stable disease or objective response after complete 8 cycles of XELOX regimen, treatment with tisleizumab and lenvatinib will be continued until tumor progression or for a maximum of 2 years.
Study NCT05558904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside
Description: Given IV
Study NCT05558904 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT05558904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT05558904 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT04246762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olokizumab
Description: Sterile solution for subcutaneous (SC) injection, 128 mg (0.8 mL injection)
Study NCT04246762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Tablets, 20 mg, oral
Study NCT06092437 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urine sodium guided diuretic algorithm
Description: Loop diuretics are administered intravenously as soon as possible after diagnosis of ADHF and continued 3dd until recompensation. Spot urine sodium is measured 2 hours after administration of the first in-hospital IV diuretic dose and repeated until the target of 100mmol/L is reached in the first 72 hours of admission (after which, UrNa will be measured once daily). When target is not met, the next dosage of loop diuretic is doubled (max 3dd 250mg furosemide) and thereafter, other diuretics (thiazide, MRA) are added. Acetazolamide in the first 72 hours is advised as background therapy in both treatment arms.
Study NCT06092437 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Treatment with IV loop diuretics left to the discretion of the treating physician. Acetazolamide in the first 72 hours is advised as background therapy in both treatment arms.
Study NCT04246762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Tablets, 100 mg, oral
Study NCT04246762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin+ Vitamin K
Description: Warfarin -Tablets 10 mg (containing 5 mg S-warfarin), oral. Vitamin K - solution for intravenous injection, 10 mg/mL ampoule, orally.
Study NCT04246762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Syrup, 2 mg/mL, oral
Study NCT05785494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Narstaende.se
Description: Web-site with supportive information, videos and chat forum targeting family caregivers of patients with life-threatening illness.
Study NCT06076382 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic ultrasound guided colorectal ESD surgery
Description: The experimental group first underwent endoscopic ultrasound examination, with a small ultrasound probe inserted into the intestinal cavity through the biopsy port. After water injection, the lesion was scanned and (1) the direction of gravity was determined. (2) fibrosis/infiltration under the mucosa, and the fibrosis was divided into F0 (no fibrosis), F1 (cold fibrosis), or F2 (severe fibrosis). (3) The lesion was divided into nine compartments. Mark submucosal fibrosis/infiltration sites, according to nine compartments. (4) Based on the results of endoscopic ultrasound scanning of the lesion, the surgeon draw up surgical approach and perform injection and dissection.
Study NCT06076382 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the traditional colorectal ESD surgery
Description: The control group underwent injection and dissection directly.
Study NCT05291052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2, orally, BID, D1-14, Q3W~Subjects can receive up to 8 cycles of the XELOX regimen (Oxaliplatin and Capecitabine). For subjects who are intolerant to XELOX regimen or have stable disease or objective response after complete 8 cycles of XELOX regimen, treatment with tisleizumab and lenvatinib will be continued until tumor progression or for a maximum of 2 years.
Study NCT05563220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elacestrant
Description: Elacestrant 86 mg, 172 mg, 258 mg or 345 mg once daily in cycles of 28 days
Study NCT05542160 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pumpkin seed extract (IRK-19)
Description: Placebo: Dietary fiber powder, two capsules/day (600 mg/day), continued use for 3 months Treatment: Pumpkin seed extract powder, two capsules/day (600 mg/day), continued use for 3 months
Study NCT05542160 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pumpkin seed extract (IRK-19)
Description: Placebo: Dietary fiber powder, two capsules/day (600 mg/day), continued use for 3 months Treatment: Pumpkin seed extract powder, two capsules/day (600 mg/day), continued use for 3 months
Study NCT05627323 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHM-1101 CAR-T cells
Description: Administered via ICT/ICV dual delivery
Study NCT05563220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Alpelisib 250 mg or 300 mg once daily in cycles of 28 days
Study NCT05563220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus 5 mg, 7.5 mg, or 10 mg once daily in cycles of 28 days
Study NCT05563220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib 400 mg or 600 mg once daily for 21 days followed by 7 days off in cycles of 28 days
Study NCT05563220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib 100 mg or 125 mg once daily for 21 days followed by 7 days off in cycles of 28 days
Study NCT05563220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Capivasertib 200 mg or 320 mg or 400 mg twice daily for 4 days on, 3 days off in cycles of 28 days
Study NCT05563220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib 100 mg or 150 mg twice daily in cycles of 28 consecutive days
Study NCT06123312 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tri-modality biopsy
Description: When the lung nodule is visualized by ultrathin bronchoscope (3mm) with RP-EBUS, Tri-modality biopsy is performed.
Study NCT06481319 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infertility Patient Navigator
Description: Assistance with infertility evaluation including scheduling appointments
Study NCT06225258 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Xanthohumol
Description: Patients, who received Xanthohumol (Chmiel-Xn-Active, SALUTIS Pharmacy, Poland) as adjunctive therapy to treatment recommended by Surviving Sepsis Campaign. Xanthohumol is administrated by the nosogastric tube three times a day \*every 8 hours) at the dose of 2 mg.\\/kg body weight for 10 days. The first dose of Xanthohumol is administrated within 4 hours after the admission to the ICU.
Study NCT04756453 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: clip-traction
Description: A endoscopic clip with a loop of tied dental floss will be attached to the lesion. The loop will then be caught by another endoscopic clip and attached to adjacent bowel wall, thus creating tension in the tissue, making dissection easier.
Study NCT04821089 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPN10200
Description: Several different doses will be administrated in a dose-escalation manner. One single injection will be injected locally into several sites across the glabellar region.
Study NCT04821089 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IPN10200 Placebo
Description: One single injection of study intervention will be injected locally into several sites across the glabellar region.
Study NCT04821089 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dysport
Description: Single administration of study intervention in stage 1 / step 2 only
Study NCT06642077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIDOFAST 40 mg/2 ml + 0.025 mg/2 ml
Description: A total of 2 ampoules of LIDOFAST 40 mg/2 ml + 0.025 mg/2 ml were injected into the sternotomy incision site and around the chest tubes of 30 patients in the experimental group. The total number and dose of opioids, the total number and dose of analgesics used to relieve the pain of the patients in the 24 hours after the injection of 2 ampules of LIDOFAST 40 mg/2 ml + 0.025 mg/2 ml, and the total number and dose of analgesics were recorded, and the patients were interviewed face-to-face 24 hours later, and PoRI was recorded. No intervention was performed on 30 patients in the control group, and standard treatment and care continued to be applied to these patients.
Study NCT04836520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390+anatrozole
Description: SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.
Study NCT04883229 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Halo Neuroscience Neurostimulator
Description: Experimental: Neurostimulation of 2 milliamps anodal (active) tDCS stimulation for 20 mins during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework. Then a washout period of no treatment, followed by a 8 weeks of sham tDCS treatment during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework.~Active comparator: Experimental: Sham tDCS stimulation for 20 mins during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework. Then a washout period of no treatment, followed by a 8 weeks of neurostimulation of 2 milliamps anodal (active) sham tDCS treatment during 1 hour speech therapy sessions, 3 times a week for 8 weeks.
Study NCT05824494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Cadonilimab 10mg/kg,every 3 weeks,IV infusion
Study NCT05824494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab paclitaxel ≤260mg/m2,every 3 weeks,IV infusion
Study NCT05019209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: House Dust Mite Allergen
Description: D. pteronyssinus lyophilisate dissolved in 5% sodium chloride solution, spray dried
Study NCT05019209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allergen-free air
Description: No allergen added to room ventilation of allergen challenge chamber
Study NCT06375512 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HZ Vaccine (IN001)
Description: Formulation for injection
Study NCT04883229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Halo Neuroscience Neurostimulator
Description: Experimental: Neurostimulation of 2 milliamps anodal (active) tDCS stimulation for 20 mins during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework. Then a washout period of no treatment, followed by a 8 weeks of sham tDCS treatment during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework.~Active comparator: Experimental: Sham tDCS stimulation for 20 mins during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework. Then a washout period of no treatment, followed by a 8 weeks of neurostimulation of 2 milliamps anodal (active) sham tDCS treatment during 1 hour speech therapy sessions, 3 times a week for 8 weeks.
Study NCT06375512 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) for injection
Study NCT06375512 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shingrix
Description: Sterile suspension for injection
Study NCT04728893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemtabrutinib
Description: Nemtabrutinib tablets administered PO QD.
Study NCT05253131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: * Selumetinib (AZD6244) is an oral selective inhibitor of the mitogen-activated protein kinase kinase (MEK) 1/2 currently in development for adult malignancies, pediatric low grade gliomas, and NF1-associated plexiform neurofibromas.~* BI is a potent and selective inhibitor of BRD4/BET bromodomain currently in development for adult malignancies.~* Durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that is currently indicated for patients with advanced urothelial carcinoma and unresectable non-small cell lung cancer.
Study NCT05715125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose A VTX958
Description: Dose A VTX958
Study NCT05715125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose B VTX958
Description: Dose B VTX958